Copper-catalyzed asymmetric allylic C–H amination of alkenes using N -arylhydroxylamines

Siva Murru, Bhanudas D Mokar, Ramesh Bista, Dominique Harakat, Jean Le Bras, Frank Fronczek, Kenneth M Nicholas, Radhey S Srivastava

► To cite this version:

Siva Murru, Bhanudas D Mokar, Ramesh Bista, Dominique Harakat, Jean Le Bras, et al.. Copper-catalyzed asymmetric allylic C–H amination of alkenes using N -arylhydroxylamines. *Organic Chemistry Frontiers*, 2021, 8 (13), pp.3228-3237. 10.1039/D1QO00223F . hal-03373934

HAL Id: hal-03373934

<https://hal.science/hal-03373934>

Submitted on 11 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copper-Catalyzed Asymmetric Allylic C-H Amination of Alkenes using *N*-arylhydroxylamines

Siva Murru,^{*a} Bhanudas D. Mokar,^b Ramesh Bista,^a Dominique Harakat,^c Jean Le Bras,^c Frank Fronczek,^d Kenneth M. Nicholas,^{*e} Radhey S. Srivastava^b

^{*} Corresponding authors. ^a Chemistry Program, School of Sciences, University of Louisiana at Monroe, Louisiana 71209, USA, E-mail: murru@ulm.edu. ^b Department of Chemistry, University of Louisiana at Lafayette, Louisiana 70504, USA, E-mail: radhey.srivastava@louisiana.edu. ^c Institut de Chimie Moléculaire de Reims – UMR 7312 CNRS-Université de Reims Champagne-Ardenne UFR des Sciences Exactes et Naturelles, BP 1039, 51687 REIMS Cedex 2, France. ^d Department of Chemistry, Louisiana State University, Baton Rouge 70803, USA. ^e Department of Chemistry and Biochemistry, University of Oklahoma, Oklahoma 73109, USA, E-mail: knicholas@ou.edu.

Abstract: The first copper-catalyzed asymmetric allylic C-H amination of alkenes using *N*-arylhydroxylamines as aminating agents is disclosed. Enantioselective C-N bond formation reactions are promoted in the presence of Cu(MeCN)₄PF₆ as a pre-catalyst and R-(+)-BINAM as a chiral ligand. This protocol delivers chiral *N*-aryl allyl amines in good yields and enantioselectivities. Data regarding the effect of ligand structure and solvents on the efficiency and enantioselectivity of amination reactions are presented. Furthermore, isolation of metal-ligand-nitroso complex, ESI-MS reaction monitoring analysis and the computational calculations provided additional insights on mechanistic pathway. DFT modeling of the reaction pathway suggests that the stereoselectivity is determined in the conversion of (BINAM)Cu(PhNO)(η^2 -alkene)⁺ to (BINAM)Cu(*N*-Ar hydroxylamine) via a concerted, asynchronous transition state for C-N bond formation. This catalytic approach features operational simplicity, high product yields with good enantioselectivity, and no byproducts except water.

Introduction: Chiral allyl amines are currently the convenient and vital compounds in organic chemistry and their synthesis is an important industrial and synthetic goal.¹ Often these

allylamines are transformed into a range of useful products by oxygenation, amination, reduction, oxidation or metathesis reactions of the double bond. Thus, chiral allylamines have been used as starting materials for the synthesis of numerous compounds such as chiral amine drugs, chiral amino acids, different alkaloids, and carbohydrate derivatives.² Remarkably, the chiral amine frameworks are present in an estimated 45% of pharmaceutical drug candidates.³ Therefore, considerable effort has been directed toward the asymmetric synthesis of chiral allylamines. In this regard, catalytic enantioselective allylic substitution has emerged as a useful synthetic tool to access chiral amines.⁴ However, these traditional approaches rely on nucleophilic substitution of allylic esters or halides, which require a pre-functionalization at the respective allylic-carbon atom. Recently, catalytic enantioselective allylic C–H amination methods⁵ have attracted significant attention from the synthetic community due to the unique atom and step economies of such processes.⁶ Most of these methods are associated with the use of complex olefin substrates, catalysts of expensive metals such as Pd, Ir, Rh and toxic chiral phosphine ligands. Additionally, these reported methods use either carbamates or chiral sulfonimidamides⁷ as nitrogen reagents and are not useful for obtaining *N*-aryl allylamines in enantioselective fashion. Aromatic amines with a stereocenter α to the nitrogen atom are important structural motifs in a number of biologically active compounds.⁸ Thus, a procedure to prepare optically active aromatic amines, in particular, an enantioselective route to *N*-aryl allylamines would be useful because of the dual amine and alkene functionality.

Despite the progress in catalytic asymmetric allylic amination, the synthesis of chiral *N*-aryl allylamines through allylic amination has proven to be very challenging and remains largely unexplored. Aromatic amines have not been used commonly in allylic amination,⁹ presumably because of their lower nucleophilicity than the more commonly used benzylamine or stabilized anionic nitrogen nucleophiles.¹⁰ A few allylic amination reactions use anilines as a nucleophilic substrate to react with either allylic halides, alcohols or esters as electrophilic substrates. (Scheme 1, path 1)¹¹ Alternatively, reaction of metal coordinated aryl aldimines with alkynes produce chiral allylamines.¹² (path 2) Additionally, cross-coupling of chiral allylamines and haloarenes have also been reported.¹³ (path 3) However, a direct enantioselective allylic *N*-aryl amination reaction using simple alkene has not been reported.

Scheme 1. Alternate approaches for making chiral N-aryl allylamines

Results and Discussion:

Following the seminal work by Sharpless on stoichiometric amination,¹⁴ several catalytic allylic amination reactions have been developed using ArNHOH, ArNO and ArNO₂ as aminating agents by us and others.¹⁵ We have studied mechanistic aspects of this reaction including, isolation of catalytic intermediates, kinetic experiments and computational studies.¹⁶ We have isolated an iron azodioxide and Cu(I)-nitrosoarene complexes, implicated as reactive intermediates in metal catalyzed allylic *N*-aryl amination reactions.¹⁷ Although the non-asymmetric version of this allylic *N*-aryl amination has been known for two decades, surprisingly, no asymmetric variant has been reported till date. Based on our experience on allylic C-H amination chemistry, we hypothesized that the kinetically controlled C-N bond formation would be feasible, in presence of a suitable metal pre-catalyst and a chiral ligand, if at least one of the substrates binds to metal center and is activated. The asymmetric environment or the chiral pocket around the metal center would then favor the selective formation of one of the allylic amine enantiomers. Our hypothesis was examined systematically and we developed the first catalytic enantioselective synthesis of chiral *N*-aryl allylamines using *N*-arylhydroxylamines and simple alkenes as reaction partners. (Scheme 1) In parallel to this study, we have developed an approach for catalytic asymmetric α -amination of carbonyl compounds.¹⁸

For initial experimentation, the reaction of 2-methyl-2-pentene (**1b**) and *N*-phenylhydroxylamine (**2a**) was selected as a model amination reaction (Table 1) and screened a

set of privileged chiral ligands¹⁹ with 1:2 metal-ligand ratio using our previously established reaction conditions.¹⁶ (Scheme 1) Preliminary investigations suggested that the tested privileged chiral ligands are not effective in terms of both the enantioselectivity and the product formation. However, surprisingly, simple amino alcohols such as R(+)-2-phenyl glycinol (**L1**, 4.9% ee) and R(+)-2'-amino-1'-binaphthalen-2-ol (**L2**, 9.3% ee) induced some enantioselectivity at room temperature. Consequently, we have varied the reaction temperatures and solvents while keeping pre-catalyst and ligand the same. Replacing the 1,4-dioxane with dichloromethane, substantially improved the enantioselectivity (**L2**, 28.2% ee) without compromising % yield. When we lowered the reaction temperature to 0° C, the % yield of desired allylamine product dropped considerably while the formation of azo and azoxybenzene byproducts significantly increased (entry 9, Table 1). Lowering catalyst loading to 5% led to decrease in yield while maintaining similar % ee. Considering these conditions and the structural features of **L1** and **L2** ligands, we tested some commercially available ligands with diol, amino alcohol, and diamine functionalities including axially chiral compounds. Except (R)-(+)-1,1'-Binaphthyl-2,2'-diamine (BINAM, **L3**, 69% ee, entry 6), none of them improved enantioselectivity. Based on these observations, we anticipated that the structurally modified R(+)-BINAM ligand may improve the electronic and steric effects of the catalytic system thereby enhancing enantioselectivity.²⁰ Accordingly, ligands **L6**, **L7** and **L9** were acquired commercially and other substituted BINAM ligands (**L5**, **L8** and **L10**) were prepared using catalytic reduction, halogenation and cross-coupling methods.²¹ We have introduced aryl substitutions on ortho-position to the amine group on BINAM. Even though they are equally effective in terms of enantioselectivity, none of them outperformed R(+)-BINAM ligand. With the systematic optimization of ligands, pre-catalysts, metal-ligand ratios and solvents at room temperature, we found that 1:2 ratio of Cu(MeCN)₄PF₆ and R(+)-BINAM using dichloromethane as a solvent worked well in terms of product yields and enantioselectivity. The initial results of this work have been patented.²²

Table 1. Selected screening data toward the catalytic synthesis of chiral *N*-aryl allylamines

Entry	Ligand	Temp (°C)	Solvent	% Yield ^a	% ee ^b
1	L1	RT	Dioxane	46	5
2	L2	RT	Dioxane	62	9
3	L2	RT	CH ₂ Cl ₂	58	28
4	L3	RT	CH ₂ Cl ₂	62	70
5	L3 ^c	RT	CH ₂ Cl ₂	65	62
6	L3^d	RT	CH₂Cl₂	67	69
7	L3	RT	CHCl ₃	54	46
8	L3	50	CH ₂ Cl ₂	68	23
9	L3	0	CH ₂ Cl ₂	6	ND
10	L4	RT	CH ₂ Cl ₂	64	73
11	L5	RT	CH ₂ Cl ₂	62	56
12	L6	RT	CH ₂ Cl ₂	53	14
13	L7	RT	CH ₂ Cl ₂	13	<5
14	L8	RT	CH ₂ Cl ₂	64	43
15	L9	RT	CH ₂ Cl ₂	58	46
16	L10	RT	CH ₂ Cl ₂	60	39

^aMeasured by GC-MS

^bMeasured by chiral GC

^c1:1 and ^d1:1.2 metal-Ligand ratio

With these optimized conditions, the scope of the substrate structure was investigated. The initial focus was set on variations of the alkenes (**1a-1h**) using *N*-phenyl hydroxylamine (**2a**) as an amine source. (Table 2) Along with the 2-methyl-2-pentene (**1b**), we have considered a set of homologous alkenes to check the effect of chain length and substitutions (**1a**, **1c**, **1d**, **1e**). Even though the product yields are comparable, enantioselectivities slightly increased as the

chain length increased. Keeping the alkene partners same, we chose a set of substituted *N*-aryl hydroxylamines (**2b-2g**) having methyl and halo-substituents at different positions on ring. Both electron-deficient and electron-rich aryl hydroxylamine partners reliably delivered desired chiral allylamine products (**3f-3t**) (Table 2). Compared to phenylhydroxylamine (**2a**) and *p*-tolyl hydroxylamine (**2b**), haloaryl hydroxylamines (**2c-2f**) produced relatively higher yields and enantioselectivities of desired *N*-aryl allylamines (**3j-3q**, **3s**, **3t**). However, when compared to the *N*-aryl allylamines **2c** (*p*-iodo) and **2e** (*m*-iodo), presence of large ‘iodo’ group at ortho-position (**2f**) negatively impacted the enantioselectivity as well as isolated yield. Moreover, the *N*-aryl hydroxylamine with para-withdrawing group (*p*-CN, **2g**) led to low conversion as well as poor enantioselectivity. It should be noted here, the chiral allylamine products with halo substituent can undergo further coupling reactions for the elaboration of more complex chiral amine compounds.²³

We have previously reported non-asymmetric amination approaches for making highly functionalized *N*-aryl aza Baylis-Hillman adducts^{15k} and aminomethyl dienes/trienes.^{17b} With that knowledge, we extended the current asymmetric catalytic approach to new substrates such as ethyl tiglate (**1f**), 3-methylpent-1,3-diene (**1g**), 2,6-dimethyloct-2,4,6-triene (**1h**). The α,β -unsaturated ester **1f** produced the corresponding chiral amine (**3u**) in good yield but with low enantioselectivity. However, enantioselectivity was increased from 23% to 51% when the same reaction performed in presence of ligand **L10**. Additionally, the diene **1g** and triene **1h** also produced the corresponding allylamines (**3v**, **3w**) with moderate enantioselectivities. (Table 2) Overall, this catalytic allylic C-H amination method works well with simple alkenes and *N*-aryl hydroxylamines.

Having developed the optimized catalytic method, we turned our attention on studying mechanistic aspects of the reaction. Over the past decade, various methodologies have been developed to enhance the ability of ESI- MS to continuously monitor catalytic reactions as they proceed which helped in determining the mechanistic pathways of several homogenous catalytic mechanisms.²⁴ We adopted the ESI-MS online reaction monitoring analysis approach to identify intermediate complexes and determine their catalytic behavior. We pursued online monitoring ESI-MS analysis in a sequential manner by injecting sample after adding each reagent. A solution of $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ and R(+)-BINAM (**L3**) in dichloromethane was stirred for 10 min, and then monitored by ESI(+)-MS. As shown in table 3, four clusters identified and are attributed to $[\text{Cu}(\text{BINAM})]^+$, $[\text{Cu}(\text{H}_2\text{O})(\text{BINAM})]^+$, $[\text{Cu}(\text{CH}_3\text{CN})(\text{BINAM})]^+$, and $[\text{Cu}(\text{BINAM})_2]^+$ respectively. The ESI(+)-MS/MS of first three complexes have a 1:1 metal-ligand ratio, whereas the last one has 1:2 metal-ligand ratio. After 10 minutes of mixing $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ and R(+)-BINAM, alkene (**1**) was added followed by slow addition of phenyl hydroxylamine (**2**) over an hour and the sample collected for ESI(+)-MS analysis. (Table 3)

Table 3. Reaction for ESI(+)-MS (5 eV) analysis and the identified clusters.

Proposed structures	Formula	Calculated	Found
$[\text{Cu}(\text{BINAM})]^+$	$\text{C}_{20}\text{H}_{16}\text{CuN}_2$	347.0609	347.0612

$[\text{Cu}(\text{H}_2\text{O})(\text{BINAM})]^+$	$\text{C}_{20}\text{H}_{18}\text{CuN}_2\text{O}$	365.0715	365.0706
$[\text{Cu}(\text{CH}_3\text{CN})(\text{BINAM})]^+$	$\text{C}_{22}\text{H}_{19}\text{CuN}_3$	388.0875	388.0863
$[\text{Cu}(\text{BINAM})_2]^+$	$\text{C}_{40}\text{H}_{32}\text{CuN}_4$	631.1923	631.1934
$[\text{Cu}(\mathbf{3})(\text{BINAM})]^+$	$\text{C}_{32}\text{H}_{32}\text{N}_3\text{Cu}$	522.1970	522.1981
$[\text{Cu}(\text{BINAM})(\mathbf{1b}\text{-H})(\text{PhN=O})]^+$	$\text{C}_{32}\text{H}_{32}\text{N}_3\text{OCu}$	537.1841	537.1844

After 1 hour, the ESI(+)-MS showed two new clusters at m/z 522 and 537, and they could be attributed to $[\text{Cu}(\mathbf{3})(\text{BINAM})]^+$ and $[\text{Cu}(\text{BINAM})(\mathbf{1b}\text{-H})(\text{PhNO})]^+$ respectively. As shown in table 3, the HRMS confirmed the formula of predicted structures (**Figure 1**). Based on these observations, we can conclude that there are two types of complexes formed in the reaction with different metal-ligand ratios i.e. 1:1 and 1:2. However, 1:1 metal-ligand complex seems to be responsible for asymmetric induction in C-N bond formation.

Figure 1. ESI(+)-MS/MS of clusters at m/z 522 and m/z 537.

To foster further understanding of catalytic activity and reaction pathway, we made attempts to isolate and characterize the Cu-BINAM complex(**4a**). Although we were not successful in obtaining a single crystal of $\text{Cu}^{\text{I}}(\text{MeCN})_4\text{PF}_6/\text{R}(+)\text{BINAM}$, our attempt with $\text{Cu}^{\text{II}}\text{OTf}_2\text{-R}(+)\text{BINAM}$ complex (**4b**) was successful and it was characterized by X-ray crystallography. As can be seen from the crystal structure provided in supplementary information (Figure S1), the metal-ligand ratio of the isolated complex is 1:2. We treated this complex **4b** with nitrosobenzene and *p*-*N,N'*-dimethyl nitrosobenzene in two separate reactions. However, we were only able to isolate the metal-ligand-nitrosoarene complex (**4c**) with *p*-*N,N'*-dimethyl nitrosobenzene but not with nitrosobenzene. The X-ray crystallographic analysis of **4c** clearly indicates that two molecules of *p*-*N,N'*-dimethyl nitrosobenzene coordinated to the metal with

the trans-octahedral geometry. (Figure S2, SI) Later we tested the catalytic activity of complex **4b** for the reaction of *N*-phenylhydroxylamine (**2a**) and 2-methyl-2-pentene (**1b**). Although expected allylamine was produced, the very low enantioselectivity (<5% ee) of the product indicates the complex **4b** is probably not responsible for the asymmetric induction. We also treated the isolated intermediate complex **4c** with 2-methyl-2-pentene, but no allylamine product was observed. We have previously established that the *p*-*N,N'*-dimethylnitrosobenzene is less reactive towards alkenes to produce allylamine.^{16,17} Nevertheless, the crystal structure of metal-ligand-nitrosoarene complex (**4c**) provides some important aspects of binding modes of ligand and nitrosoarene, and the nitroso-activation for the amination reactions.

The results of ESI-MS reaction monitoring analysis and isolation of copper-complexes prompted us to consider a theoretical (computational) investigation to predict possible intermediates and the reaction pathway for the asymmetric allylic amination. A potential reaction pathway that accounts for the enantioselectivity was addressed with the DFT-B3LYP method (SMD solvent model for CH₂Cl₂). Various (diamine)_xCu(I,II)(alkene)(PhNO)⁺ species were evaluated for the reaction of *N*-phenyl hydroxylamine (**2a**) with 2-methyl-2-butene (**1b**) using R(+)-BINAM (**L3**) as the chiral ligand. An energetically viable pathway for the asymmetric amination that affords the corresponding chiral allylamine ($\Delta G_{\text{calc}} = -23.7$ kcal) was found starting with (R-BINAM)Cu(I)(alkene)(PhNO)⁺ **A** as a key intermediate (Scheme 2). Two alkene facial isomers of **A** were optimized (*pro-R* and *pro-S*) with the *pro-S* isomer being more stable by 0.4 kcal/mol. Two isomeric C-N bond-forming transition states (TS) **B**, generated from the facial isomers of **A**, could be located with activation energies of 22.2 and 22.9 kcal/mol, a difference ($\Delta\Delta G^*$) of 0.7 kcal. The lower activation energy from the *pro-S* isomer predicts the stereoselective formation of the (*S*)-allylamine with approximately 54% ee with the R(+)-BINAM ligand, in good agreement with our experimental results showing the (*S*)-allylamine (**3a**) being the major enantiomer with 53% ee.

Scheme 2. Plausible mechanistic pathway of Cu-catalyzed asymmetric allylic amination

The transition state **B** shows that C-N bond formation is initiated asynchronously before C-H bond-breaking (Figure 2). The preferred regioselectivity for attack at the less-substituted alkene is previewed by the differing C-N distances (1.84 vs. 2.6 Å) in the TS. The stepwise nature of the **A** to allyl hydroxylamine **F** conversion is comparable to that proposed for the corresponding uncatalyzed ArNO/alkene ene-reaction.²⁵ As C-N bond formation completes from TS **B**, two intermediates of comparable energy **C** or **D** may form; **C** is a Cu-coordinated aziridine *N*-oxide and **D** is a Cu-complexed *N*-allyl hydroxylamine. In the next step, the free aziridine *N*-oxide **E** detaches from complex **C** while the latter involves in association of alkene to generate (BINAM)Cu(alkene)⁺. Rapid rearrangement of the aziridine *N*-oxide **E** via H-transfer and ring opening, a known process that occurs stereospecifically,²⁵ would produce the allyl hydroxylamine **F**. Alternatively, the hydroxylamine **F** could form via dissociation from complex **D**. Subsequent Cu(I) reduction of the hydroxylamine would give the allylamine **G** and (diamine)Cu(II) that can re-enter the catalytic cycle after one-electron reduction.

Figure 2. Favored *pro-S* transition state for the reaction of $(R\text{-BINAM})\text{Cu}(\text{PhNO})(\eta^2\text{-2-methyl-2-butene})^+$ leading to the (S) -hydroxylamine **F**; N-C3 = 1.84 Å, N-C2 = 2.46 Å; C=grey, H=white, N=blue, O=red, Cu=bronze.

Conclusions:

We have developed a novel catalytic asymmetric allylic C-H amination approach for the amination of simple alkenes with *N*-arylhydroxylamines. This procedure can be operated without any special precautions as it works at room temperature utilizing an *in situ* generated copper catalytic system i.e. the combination of $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ and $R(+)\text{-BINAM}$. We have extended this approach to access other useful chiral amine compounds employing α,β -unsaturated carbonyl compound, diene and triene as alkene partners. We have also established the configuration of major enantiomers obtained in this reaction. In order to gain additional insights on the reaction mechanism, we have monitored the reaction with ESI-MS analysis, isolated metal complexes and predicted the possible intermediates based on computational studies. Overall, this simple and straight forward methodology marks a significant step forward in the synthesis of the chiral *N*-aryl allylamine scaffolds. DFT modeling of the reaction pathway suggests that the stereoselectivity is determined in the conversion of $(\text{BINAM})\text{Cu}(\text{PhNO})(\eta^2\text{-alkene})^+$ to $(\text{BINAM})\text{Cu}(\text{N-Ar hydroxylamine})$ via a concerted, asynchronous transition state for C-N bond formation.

Conflicts of Interest:

There are no conflicts of interest

Acknowledgements:

The research work reported in this publication was supported by NSF, 1566561 (to RSS and SM) and NIH-NIGMS, 1R15GM120663-01, (to RSS), LBRN Pilot Award (to SM) from IDeA Networks of Biomedical Research Excellence (INBRE), National Institute of General

Medical Sciences of the National Institutes of Health (NIGMS/NIH) grant number P2O GM103424-18. KN acknowledges support from the National Science Foundation (CHE 1566213), an A.C. Cope Scholar award and generous computer time from the OU Supercomputing Center for Education & Research (O.S.C.E.R.).

Notes and References:

1. (a) Q. Cheng, H.-F. Tu, C. Zheng, J.-P. Qu, G. Helmchen and S.-L. You, *Chem. Rev.*, 2019, **119**, 1855–1969; (b) K. Manna, H. M. Begam, K. Samanta and R. Jana, *Org. Lett.*, 2020, **22**, 7443–7449; (c) P. Tosatti, A. Nelsona and S. P. Marsdena, *Org. Biomol. Chem.*, 2012, **10**, 3147–3163; (d) J. F. Hartwig and M. J. Pouy, *Topics in Organometallic Chemistry*, 2011, **34**, 169–208.
2. (a) M. Johannsen and K. A. Jørgensen, *Chem. Rev.*, 1998, **98**, 1689–1708; (b) O. Belda and C. Moberg, *Acc. Chem. Res.*, 2004, **37**, 159–167.
3. D. Ghislieri, A. P. Green, M. Pontini, S. C. Willies, I. Rowles, A. Frank, G. Grogan and N. J. Turner, *J. Am. Chem. Soc.* 2013, **135**, 10863–10869.
4. Recent reviews: (a) F. Collet, R. H. Dodd and P. Dauban, *Chem. Commun.*, 2009, 5061–5074; (b) F. Collet, C. Lescot and P. Dauban, *Chem. Soc. Rev.*, 2011, **40**, 1926–1936; (c) T. A. Ramirez, B. Zhao and Y. Shi, *Chem. Soc. Rev.*, 2012, **41**, 931–942; (d) C.-X. Zhuo, C. Zheng and S.-L. You, *Acc. Chem. Res.*, 2014, **47**, 2558–2573; (e) N. A. Butt and W. Zhang, *Chem. Soc. Rev.*, 2015, **44**, 7929–7967; (f) J. Buendia, G. Grelrier and P. Dauban, *Advances in Organometallic Chemistry*, 2015, **64**, 77–118; (g) R. A. Fernandes and J. L. Nallasivam, *Org. Biomol. Chem.*, 2019, **17**, 8647–8672; Iridium Catalyzed AAA Articles; (h) D. Polet, A. Alexakis, A. Tissot-Croset, C. Corminboeuf and K. Ditrach, *Chem. Eur. J.*, 2006, **12**, 3596–3609; (i) J. A. Raskatov, S. Spiess, C. Gnam, K. Brö dner, F. Rominger and G. Helmchen, *Chem. Eur. J.*, 2010, **16**, 6601–66017; (j) P. Tosatti, J. Horn, A. J. Campbell, D. House, A. Nelson, and S. P. Marsden, *Adv. Synth. Catal.*, 2010, **352**, 3153–3157; (k) K.-Y. Ye, L.-X. Dai, and S.-L. You, *Chem. Eur. J.*, 2014, **20**, 3040–3044; (l) C. C. Malakar and G. Helmchen, *Chem. Eur. J.*, 2015, **21**, 7127–7134.
5. (a) C. G. Newton, S.-G. Wang, C. C. Oliveira and N. Cramer, *Chem. Rev.* 2017, **117**, 8908–8976; (b) H. Lei and T. Rovis, *J. Am. Chem. Soc.*, 2019, **141**, 2268–2273; (c) J. M. Alderson, A. M. Phelps, R. J. Scamp, N. Dolan and J. M. Schomaker, *J. Am. Chem. Soc.*, 2014, **136**, 16720–16723; (d) A. Sharma and J. F. Hartwig, *J. Am. Chem. Soc.*, 2013, **135**, 17983–17989; (e) J. W. Rigoli, C. D. Weatherly, J. M. Alderson, B. T. Vo, J. M. Schomaker, *J. Am. Chem. Soc.*, 2013, **135**, 17238–17241; (f) R. D. Grigg, J. W. Rigoli, S. D. Pearce and J. M. Schomaker, *Org. Lett.*, 2012, **14**, 280–283.
6. (a) S. M. Paradine and M. C. White, *J. Am. Chem. Soc.*, 2012, **134**, 2036–2039; (b) S. A. Reed, A. R. Mazzotti and M. C. White, *J. Am. Chem. Soc.*, 2009, **131**, 11701–11706; (c) G. T. Rice and White, M. C., *J. Am. Chem. Soc.*, 2009, **131**, 11707–11711; (d) S. A. Reed and M. C. White, *J. Am. Chem. Soc.*, 2008, **130**, 3316–3318; (e) K. J. Fraunhofer and M. C. White, *J. Am. Chem. Soc.*, 2007, **129**, 7274–7276; (f) M. E. Harvey, D. G.; Musaev and J. D. Bois, *J. Am. Chem. Soc.*, 2011, **133**, 17207–17216; (g) B. M. Trost, S. Malhotra, D. E. Olson, A. Maruniak and J. D. Bois, *J. Am. Chem. Soc.*, 2009, **131**, 4190–4191; (h) D. N. Zalatan and J. D. Bois, *J. Am. Chem. Soc.*, 2008, **130**, 9220–9221. (i) D. Markovic and J. F. Hartwig, *J. Am. Chem. Soc.*,

- 2007, **129**, 11680–11681; (j) Y. Yamashita, A. Gopalarathnam and J. F. Hartwig, *J. Am. Chem. Soc.*, 2007, **129**, 7508–7509; (k) S. Shekhar, B. Trantow, A. Leitner and J. F. Hartwig, *J. Am. Chem. Soc.*, 2006, **128**, 11770–11771. (l) A. Leitner, S. Shekhar, M. J. Pouy and J. F. Hartwig, *J. Am. Chem. Soc.*, 2005, **127**, 15506–15514; (m) C. A. Kiener, C. Shu, C. Incarvito and J. F. Hartwig, *J. Am. Chem. Soc.*, 2003, **125**, 14272–14273; (n) O. Lo'ber, M. Kawatsura and J. F. Hartwig, *J. Am. Chem. Soc.*, 2001, **123**, 4366–4367.
7. (a) Y. Nishioka, T. Uchida and T. Katsuki, *Angew. Chem. Int. Ed.* 2013, **52**, 1739–1742; (b) J. S. Clark and C. Roche, *Chem. Commun.*, 2005, 5175–5177; (c) C. Liang, F. Collet, F. Robert-Peillard, P. Müller, R. H. Dodd and P. Dauban, *J. Am. Chem. Soc.*, 2008, **130**, 343–350; (d) F. Collet, C. Lescot, C. Liang and P. Dauban, *Dalton Trans.*, 2010, **39**, 10401–10413; (e) C. Lescot, B. Darses, F. Collet, P. Retailleau and P. Dauban, *J. Org. Chem.*, 2012, **77**, 7232–7240; (f) R. Rey-Rodriguez, G. Jestin, V. Gandon, G. Grelier, P. Retailleau, B. Darses, P. Dauban, and I. Gillaizeau, *Adv. Synth. Catal.*, 2018, **360**, 513–518.
8. (a) B. M. Trost, *Chem. Pharm. Bull.*, 2002, **50**, 1–14; (b) B. M. Trost and M. L. Crawley, *Chem. Rev.*, 2003, **103**, 2921–2943; (c) B. M. Trost, *J. Org. Chem.*, 2004, **69**, 5813–5837; (d) M. Mori, *Chem. Pharm. Bull.*, 2005, **53**, 457–470; (e) R. L. Grange, E. A. Clizbe and P. A. Evans, *Synthesis*, 2016, **48**, 2911–2968.
9. (a) C. T. Shu, A. Leitner and J. F. Hartwig, *Angew. Chem. Int. Ed.*, 2004, **43**, 4797–4800; (b) F. Ozawa, H. Okamoto, S. Kawagishi, S. Yamamoto, T. Minami and M. Yoshifuji, *J. Am. Chem. Soc.* 2002, **124**, 10968–10969; (c) S.-C. Yang and C.-W. Hung, *J. Org. Chem.* 1999, **64**, 5000–5001.
10. F. Benfatti, G. Cardillo, L. Gentilucci, E. Mosconi and A. Tolomelli, *Org. Lett.*, 2008, **10**, 2425–2428 and references cited therein.
11. (a) R. Takeuchi, N. Ue, K. Tanabe, K. Yamashita, and N. Shiga, *J. Am. Chem. Soc.* 2001, **123**, 9525–9534; (b) D. Marković and J. F. Hartwig, *J. Am. Chem. Soc.* 2007, **129**, 11680–11681; (c) S.-C. Yang and Y.-C. Tsai, *Organometallics*, 2001, **20**, 763–770; (d) Y.-J. Shue, S.-C. Yang and H.-C. Lai, *Tetrahedron Letters*, 2003, **44**, 1481–1485; (e) S.-C. Yang, Y.-C. Tsai and Y.-J. Shue, *Organometallics*, 2001, **20**, 5326–5330; (f) K. Chen, Y. Li, S. A. Pullarkat and P.-H. Leung, *Adv. Synth. Catal.*, 2012, **354**, 83–87; (g) I. Solic, D. Reich, J. Lim and R. W. Bates, *Asian J. Org. Chem.* 2017, **6**, 658–661. (h) W. Guo, A. Cai, J. Xie, A.W. Kleij, *Angew. Chem. Int. Ed.* 2017, **56**, 11797–11801. (i) S.W. Kim; L.A. Schwartz; J. R. Zbieg; C. E. Stivala; M. J. Krische, *J. Am. Chem. Soc.* 2019, **141**, 671–676. (j) Cai, A.; Guo, W.; Martínez-Rodríguez, L.; Kleij, A. W. *J. Am. Chem. Soc.* 2016, **138**, 14194–14197.
12. R. B. Grossman, W. M. Davis and S. L. Buchwald, *J. Am. Chem. Soc.* 1991, **113**, 2321–2322.
13. S. C. Cosgrove, M. P. Thompson, S. T. Ahmed, F. Parmeggiani, N. J. Turner, *Angew. Chem. Int. Ed.* 2020, **59**, 18156–18160.
14. (a) K. B. Sharpless, T. Hori, L. K. Truesdale, C. O. Dietrich, *J. Am. Chem. Soc.*, 1976, **98**, 269–271; (b) L. S. Liebeskind, K. B. Sharpless, R. D. Wilson, J. A. Ibers, *J. Am. Chem. Soc.*, 1978, **100**, 7061–7063.
15. (a) M. Johannsen and K. A. Jørgensen, *J. Org. Chem.*, 1994, **59**, 214–216; (b) R. S. Srivastava, and K. M. Nicholas, *J. Org. Chem.*, 1994, **59**, 5365–5371; (c) R. S. Srivastava and K. M. Nicholas, *Tetrahedron Lett.*, 1994, **35**, 8739–8742; (d) R. S. Srivastava, M. A. Khan and K. M. Nicholas, *J. Am. Chem. Soc.*, 1996, **118**, 3311–3312; (e) R. S. Srivastava and K. M. Nicholas, *J. Am. Chem. Soc.*, 1997, **119**, 3302–3310; (f) C.-M. Ho and T.-C. Lau, *New J. Chem.*, 2000, **24**, 859–863; (g) R. S. Srivastava, M. Kolel-Vetil and K. M. Nicholas, *Tetrahedron Lett.*, 2002, **43**,

- 931–934; (h) G. A. Hogan, A. A. Gallo, K. M. Nicholas and R. S. Srivastava, *Tetrahedron Letters*, 2002, **43**, 9505–9508; (i) R. S. Srivastava, *Tetrahedron Lett.*, 2003, **44**, 3271–3274; (j) R. S. Srivastava, R. Bertrand III, A. A. Gallo and K. M. Nicholas, *Tetrahedron Lett.*, 2011, **52**, 3478–3480; (k) S. Murru, A. A. Gallo and R. S. Srivastava, *J. Org. Chem.*, 2012, **77**, 7119–7123; (l) S. Murru, B. McGough and R. S. Srivastava, *Org. Biomol. Chem.*, 2014, **12**, 9133–9138.
16. R. S. Srivastava, N. R. Tarver and K. M. Nicholas, *J. Am. Chem. Soc.*, 2007, **129**, 15250–15258.
17. (a) R. S. Srivastava, M. A. Khan and K. M. Nicholas, *J. Am. Chem. Soc.*, 2005, **127**, 7278–7279; (b) S. Murru, R. S. Srivastava, *Eur. J. Org. Chem.*, 2014, 2174–2181.
18. R. K. R. Singh, T. N.V. Karsili and R. Srivastava, *Mol. Cat.* 2020, **493**, 111067.
19. (a) Synthetic catalysts which are enantioselective over a wide range of different reactions were defined as “privileged” by Jacobsen, see: T. P. Yoon and E. N. Jacobsen, *Science*, 2003, **299**, 1691. (b) Privileged Chiral Ligands and Catalysts; Q.-L. Zhou; Wiley-VCH: Weinheim, 2011.
20. Atropisomerism and Axial Chirality Edited By: José M Lassaletta (Instituto de Investigaciones Químicas (CSIC-US), Spain), 2019, 447-488, Chapter 6: Axially Chiral X,X-Ligands (X = N, O) for Asymmetric Metal-Catalyzed Reactions by Jun Ying and Lin Pu.
21. T. Kano, Y. Tanaka, K. Osawa, T. Yurino and K. Maruoka, *J. Org. Chem.* 2008, **73**, 7387–7389.
22. R. S. Srivastava and S. Murru, U.S. Pat. Appl. Publ. 20160304538, 20 Oct 2016.
23. J. I. Ayogu and E. A. Onoabedje, *Catal. Sci. Technol.*, 2019, **9**, 5233–5255.
24. (a) C. H. Beierlein, B. Breit, R. A. Paz Schmidt and D. A. Plattner, *Organometallics*, 2010, **29**, 2521–2532. (b) Z. Ahmadi and J. S. McIndoe, *Chem. Commun.*, 2013, **49**, 11488. (c) Zhang, X., Pei, M., Wu, D. S. Yang and Z. Le, *Sci Rep* 2019, **9**, 19279. (d) L. P. E. Yunker, R. L. Stoddard, J. S. McIndoe, *J. Mass Spectrom.* 2014, **49**, 1– 8. (e) J. Mehara, J. Roithová *Chemical Science* 2020, **11**, 11960-11972.
25. (a) J. E. Baldwin, A. K. Bhatnagar, S. C. Choi and T. J. Shortridge, *J. Am. Chem. Soc.*, 1971, **93**, 4082–4084; (b) C. A. Seymour and F. D. Greene, *J. Org. Chem.*, 1982, **47**, 5227–5229.